Global Ophthalmology Disorders Drug Market Size, Status and Forecast 2024-2031

Report ID: 934784 | Published Date: Jan 2025 | No. of Page: 127 | Base Year: 2024 | Rating: 3.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Oral
        1.2.3 Injection
        1.2.4 External Use
    1.3 Market by Application
        1.3.1 Global Ophthalmology Disorders Drug Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Juvenile Macular Degeneration (Stargardt Disease)
        1.3.3 Leber Congenital Amaurosis (LCA)
        1.3.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
        1.3.5 Usher Syndrome
        1.3.6 Retinitis Pigmentosa (Retinitis)
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Ophthalmology Disorders Drug Market Perspective (2016-2027)
    2.2 Ophthalmology Disorders Drug Growth Trends by Regions
        2.2.1 Ophthalmology Disorders Drug Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Ophthalmology Disorders Drug Historic Market Share by Regions (2016-2021)
        2.2.3 Ophthalmology Disorders Drug Forecasted Market Size by Regions (2022-2027)
    2.3 Ophthalmology Disorders Drug Industry Dynamic
        2.3.1 Ophthalmology Disorders Drug Market Trends
        2.3.2 Ophthalmology Disorders Drug Market Drivers
        2.3.3 Ophthalmology Disorders Drug Market Challenges
        2.3.4 Ophthalmology Disorders Drug Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Ophthalmology Disorders Drug Players by Revenue
        3.1.1 Global Top Ophthalmology Disorders Drug Players by Revenue (2016-2021)
        3.1.2 Global Ophthalmology Disorders Drug Revenue Market Share by Players (2016-2021)
    3.2 Global Ophthalmology Disorders Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Ophthalmology Disorders Drug Revenue
    3.4 Global Ophthalmology Disorders Drug Market Concentration Ratio
        3.4.1 Global Ophthalmology Disorders Drug Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Ophthalmology Disorders Drug Revenue in 2020
    3.5 Ophthalmology Disorders Drug Key Players Head office and Area Served
    3.6 Key Players Ophthalmology Disorders Drug Product Solution and Service
    3.7 Date of Enter into Ophthalmology Disorders Drug Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Ophthalmology Disorders Drug Breakdown Data by Type
    4.1 Global Ophthalmology Disorders Drug Historic Market Size by Type (2016-2021)
    4.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2022-2027)

5 Ophthalmology Disorders Drug Breakdown Data by Application
    5.1 Global Ophthalmology Disorders Drug Historic Market Size by Application (2016-2021)
    5.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Ophthalmology Disorders Drug Market Size (2016-2027)
    6.2 North America Ophthalmology Disorders Drug Market Size by Type
        6.2.1 North America Ophthalmology Disorders Drug Market Size by Type (2016-2021)
        6.2.2 North America Ophthalmology Disorders Drug Market Size by Type (2022-2027)
        6.2.3 North America Ophthalmology Disorders Drug Market Size by Type (2016-2027)
    6.3 North America Ophthalmology Disorders Drug Market Size by Application
        6.3.1 North America Ophthalmology Disorders Drug Market Size by Application (2016-2021)
        6.3.2 North America Ophthalmology Disorders Drug Market Size by Application (2022-2027)
        6.3.3 North America Ophthalmology Disorders Drug Market Size by Application (2016-2027)
    6.4 North America Ophthalmology Disorders Drug Market Size by Country
        6.4.1 North America Ophthalmology Disorders Drug Market Size by Country (2016-2021)
        6.4.2 North America Ophthalmology Disorders Drug Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Ophthalmology Disorders Drug Market Size (2016-2027)
    7.2 Europe Ophthalmology Disorders Drug Market Size by Type
        7.2.1 Europe Ophthalmology Disorders Drug Market Size by Type (2016-2021)
        7.2.2 Europe Ophthalmology Disorders Drug Market Size by Type (2022-2027)
        7.2.3 Europe Ophthalmology Disorders Drug Market Size by Type (2016-2027)
    7.3 Europe Ophthalmology Disorders Drug Market Size by Application
        7.3.1 Europe Ophthalmology Disorders Drug Market Size by Application (2016-2021)
        7.3.2 Europe Ophthalmology Disorders Drug Market Size by Application (2022-2027)
        7.3.3 Europe Ophthalmology Disorders Drug Market Size by Application (2016-2027)
    7.4 Europe Ophthalmology Disorders Drug Market Size by Country
        7.4.1 Europe Ophthalmology Disorders Drug Market Size by Country (2016-2021)
        7.4.2 Europe Ophthalmology Disorders Drug Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Ophthalmology Disorders Drug Market Size (2016-2027)
    8.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type
        8.2.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2016-2027)
    8.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application
        8.3.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2016-2027)
    8.4 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region
        8.4.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Ophthalmology Disorders Drug Market Size (2016-2027)
    9.2 Latin America Ophthalmology Disorders Drug Market Size by Type
        9.2.1 Latin America Ophthalmology Disorders Drug Market Size by Type (2016-2021)
        9.2.2 Latin America Ophthalmology Disorders Drug Market Size by Type (2022-2027)
        9.2.3 Latin America Ophthalmology Disorders Drug Market Size by Type (2016-2027)
    9.3 Latin America Ophthalmology Disorders Drug Market Size by Application
        9.3.1 Latin America Ophthalmology Disorders Drug Market Size by Application (2016-2021)
        9.3.2 Latin America Ophthalmology Disorders Drug Market Size by Application (2022-2027)
        9.3.3 Latin America Ophthalmology Disorders Drug Market Size by Application (2016-2027)
    9.4 Latin America Ophthalmology Disorders Drug Market Size by Country
        9.4.1 Latin America Ophthalmology Disorders Drug Market Size by Country (2016-2021)
        9.4.2 Latin America Ophthalmology Disorders Drug Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Ophthalmology Disorders Drug Market Size (2016-2027)
    10.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type
        10.2.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2016-2027)
    10.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application
        10.3.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2016-2027)
    10.4 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country
        10.4.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Sanofi
        11.1.1 Sanofi Company Details
        11.1.2 Sanofi Business Overview
        11.1.3 Sanofi Ophthalmology Disorders Drug Introduction
        11.1.4 Sanofi Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.1.5 Sanofi Recent Development
    11.2 Bayer
        11.2.1 Bayer Company Details
        11.2.2 Bayer Business Overview
        11.2.3 Bayer Ophthalmology Disorders Drug Introduction
        11.2.4 Bayer Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.2.5 Bayer Recent Development
    11.3 Bausch + Lomb
        11.3.1 Bausch + Lomb Company Details
        11.3.2 Bausch + Lomb Business Overview
        11.3.3 Bausch + Lomb Ophthalmology Disorders Drug Introduction
        11.3.4 Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.3.5 Bausch + Lomb Recent Development
    11.4 Novartis
        11.4.1 Novartis Company Details
        11.4.2 Novartis Business Overview
        11.4.3 Novartis Ophthalmology Disorders Drug Introduction
        11.4.4 Novartis Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.4.5 Novartis Recent Development
    11.5 Usher Syndrome
        11.5.1 Usher Syndrome Company Details
        11.5.2 Usher Syndrome Business Overview
        11.5.3 Usher Syndrome Ophthalmology Disorders Drug Introduction
        11.5.4 Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.5.5 Usher Syndrome Recent Development
    11.6 Takeda Pharmaceutical
        11.6.1 Takeda Pharmaceutical Company Details
        11.6.2 Takeda Pharmaceutical Business Overview
        11.6.3 Takeda Pharmaceutical Ophthalmology Disorders Drug Introduction
        11.6.4 Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.6.5 Takeda Pharmaceutical Recent Development
    11.7 Roche
        11.7.1 Roche Company Details
        11.7.2 Roche Business Overview
        11.7.3 Roche Ophthalmology Disorders Drug Introduction
        11.7.4 Roche Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.7.5 Roche Recent Development
    11.8 Pfizer
        11.8.1 Pfizer Company Details
        11.8.2 Pfizer Business Overview
        11.8.3 Pfizer Ophthalmology Disorders Drug Introduction
        11.8.4 Pfizer Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.8.5 Pfizer Recent Development
    11.9 Allergan
        11.9.1 Allergan Company Details
        11.9.2 Allergan Business Overview
        11.9.3 Allergan Ophthalmology Disorders Drug Introduction
        11.9.4 Allergan Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.9.5 Allergan Recent Development
    11.10 Gilead Sciences
        11.10.1 Gilead Sciences Company Details
        11.10.2 Gilead Sciences Business Overview
        11.10.3 Gilead Sciences Ophthalmology Disorders Drug Introduction
        11.10.4 Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.10.5 Gilead Sciences Recent Development
    11.11 Kubota Pharmaceutical
        11.11.1 Kubota Pharmaceutical Company Details
        11.11.2 Kubota Pharmaceutical Business Overview
        11.11.3 Kubota Pharmaceutical Ophthalmology Disorders Drug Introduction
        11.11.4 Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.11.5 Kubota Pharmaceutical Recent Development
    11.12 Alkeus Pharmaceuticals
        11.12.1 Alkeus Pharmaceuticals Company Details
        11.12.2 Alkeus Pharmaceuticals Business Overview
        11.12.3 Alkeus Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.12.4 Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.12.5 Alkeus Pharmaceuticals Recent Development
    11.13 Astellas Pharma
        11.13.1 Astellas Pharma Company Details
        11.13.2 Astellas Pharma Business Overview
        11.13.3 Astellas Pharma Ophthalmology Disorders Drug Introduction
        11.13.4 Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.13.5 Astellas Pharma Recent Development
    11.14 Ferrer Corporate
        11.14.1 Ferrer Corporate Company Details
        11.14.2 Ferrer Corporate Business Overview
        11.14.3 Ferrer Corporate Ophthalmology Disorders Drug Introduction
        11.14.4 Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.14.5 Ferrer Corporate Recent Development
    11.15 Amgen Inc
        11.15.1 Amgen Inc Company Details
        11.15.2 Amgen Inc Business Overview
        11.15.3 Amgen Inc Ophthalmology Disorders Drug Introduction
        11.15.4 Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.15.5 Amgen Inc Recent Development
    11.16 Editas Medicine Inc
        11.16.1 Editas Medicine Inc Company Details
        11.16.2 Editas Medicine Inc Business Overview
        11.16.3 Editas Medicine Inc Ophthalmology Disorders Drug Introduction
        11.16.4 Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.16.5 Editas Medicine Inc Recent Development
    11.17 ProQR Therapeutics NV
        11.17.1 ProQR Therapeutics NV Company Details
        11.17.2 ProQR Therapeutics NV Business Overview
        11.17.3 ProQR Therapeutics NV Ophthalmology Disorders Drug Introduction
        11.17.4 ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.17.5 ProQR Therapeutics NV Recent Development
    11.18 ReNeuron
        11.18.1 ReNeuron Company Details
        11.18.2 ReNeuron Business Overview
        11.18.3 ReNeuron Ophthalmology Disorders Drug Introduction
        11.18.4 ReNeuron Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.18.5 ReNeuron Recent Development
    11.18 Amarantus BioScience
        11.25.1 Amarantus BioScience Company Details
        11.25.2 Amarantus BioScience Business Overview
        11.25.3 Amarantus BioScience Ophthalmology Disorders Drug Introduction
        11.25.4 Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.25.5 Amarantus BioScience Recent Development
    11.20 Ocugen
        11.20.1 Ocugen Company Details
        11.20.2 Ocugen Business Overview
        11.20.3 Ocugen Ophthalmology Disorders Drug Introduction
        11.20.4 Ocugen Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.20.5 Ocugen Recent Development
    11.21 ReGenX Biosciences
        11.21.1 ReGenX Biosciences Company Details
        11.21.2 ReGenX Biosciences Business Overview
        11.21.3 ReGenX Biosciences Ophthalmology Disorders Drug Introduction
        11.21.4 ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.21.5 ReGenX Biosciences Recent Development
    11.22 Sucampo Pharmaceuticals
        11.22.1 Sucampo Pharmaceuticals Company Details
        11.22.2 Sucampo Pharmaceuticals Business Overview
        11.22.3 Sucampo Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.22.4 Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.22.5 Sucampo Pharmaceuticals Recent Development
    11.23 Orphagen Pharmaceuticals
        11.23.1 Orphagen Pharmaceuticals Company Details
        11.23.2 Orphagen Pharmaceuticals Business Overview
        11.23.3 Orphagen Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.23.4 Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.23.5 Orphagen Pharmaceuticals Recent Development
    11.24 Okuvision
        11.24.1 Okuvision Company Details
        11.24.2 Okuvision Business Overview
        11.24.3 Okuvision Ophthalmology Disorders Drug Introduction
        11.24.4 Okuvision Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.24.5 Okuvision Recent Development
    11.25 Second Sight Medical
        11.25.1 Second Sight Medical Company Details
        11.25.2 Second Sight Medical Business Overview
        11.25.3 Second Sight Medical Ophthalmology Disorders Drug Introduction
        11.25.4 Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.25.5 Second Sight Medical Recent Development
    11.26 Acucela
        11.26.1 Acucela Company Details
        11.26.2 Acucela Business Overview
        11.26.3 Acucela Ophthalmology Disorders Drug Introduction
        11.26.4 Acucela Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.26.5 Acucela Recent Development
    11.27 Stealth BioTherapeutics
        11.27.1 Stealth BioTherapeutics Company Details
        11.27.2 Stealth BioTherapeutics Business Overview
        11.27.3 Stealth BioTherapeutics Ophthalmology Disorders Drug Introduction
        11.27.4 Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.27.5 Stealth BioTherapeutics Recent Development
    11.28 Sun Pharma Advanced Research Company
        11.28.1 Sun Pharma Advanced Research Company Company Details
        11.28.2 Sun Pharma Advanced Research Company Business Overview
        11.28.3 Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Introduction
        11.28.4 Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.28.5 Sun Pharma Advanced Research Company Recent Development
    11.29 AmpliPhi Biosciences
        11.29.1 AmpliPhi Biosciences Company Details
        11.29.2 AmpliPhi Biosciences Business Overview
        11.29.3 AmpliPhi Biosciences Ophthalmology Disorders Drug Introduction
        11.29.4 AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.29.5 AmpliPhi Biosciences Recent Development
    11.30 Applied Genetic Technologies
        11.30.1 Applied Genetic Technologies Company Details
        11.30.2 Applied Genetic Technologies Business Overview
        11.30.3 Applied Genetic Technologies Ophthalmology Disorders Drug Introduction
        11.30.4 Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.30.5 Applied Genetic Technologies Recent Development
    11.31 Asklepios BioPharmaceutical
        11.31.1 Asklepios BioPharmaceutical Company Details
        11.31.2 Asklepios BioPharmaceutical Business Overview
        11.31.3 Asklepios BioPharmaceutical Ophthalmology Disorders Drug Introduction
        11.31.4 Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.31.5 Asklepios BioPharmaceutical Recent Development
    11.32 Biovista
        11.32.1 Biovista Company Details
        11.32.2 Biovista Business Overview
        11.32.3 Biovista Ophthalmology Disorders Drug Introduction
        11.32.4 Biovista Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.32.5 Biovista Recent Development
    11.33 Spark Therapeutics
        11.33.1 Spark Therapeutics Company Details
        11.33.2 Spark Therapeutics Business Overview
        11.33.3 Spark Therapeutics Ophthalmology Disorders Drug Introduction
        11.33.4 Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.33.5 Spark Therapeutics Recent Development
    11.34 Caladrius Biosciences
        11.34.1 Caladrius Biosciences Company Details
        11.34.2 Caladrius Biosciences Business Overview
        11.34.3 Caladrius Biosciences Ophthalmology Disorders Drug Introduction
        11.34.4 Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.34.5 Caladrius Biosciences Recent Development
    11.35 Dompe Farmaceutici
        11.35.1 Dompe Farmaceutici Company Details
        11.35.2 Dompe Farmaceutici Business Overview
        11.35.3 Dompe Farmaceutici Ophthalmology Disorders Drug Introduction
        11.35.4 Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.35.5 Dompe Farmaceutici Recent Development
    11.36 Dormant Projects
        11.36.1 Dormant Projects Company Details
        11.36.2 Dormant Projects Business Overview
        11.36.3 Dormant Projects Ophthalmology Disorders Drug Introduction
        11.36.4 Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.36.5 Dormant Projects Recent Development
    11.37 Grupo Ferrer Internacional
        11.37.1 Grupo Ferrer Internacional Company Details
        11.37.2 Grupo Ferrer Internacional Business Overview
        11.37.3 Grupo Ferrer Internacional Ophthalmology Disorders Drug Introduction
        11.37.4 Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.37.5 Grupo Ferrer Internacional Recent Development
    11.38 ID Pharma
        11.38.1 ID Pharma Company Details
        11.38.2 ID Pharma Business Overview
        11.38.3 ID Pharma Ophthalmology Disorders Drug Introduction
        11.38.4 ID Pharma Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.38.5 ID Pharma Recent Development
    11.39 InFlectis BioScience
        11.39.1 InFlectis BioScience Company Details
        11.39.2 InFlectis BioScience Business Overview
        11.39.3 InFlectis BioScience Ophthalmology Disorders Drug Introduction
        11.39.4 InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.39.5 InFlectis BioScience Recent Development
    11.40 Ionis Pharmaceuticals
        11.40.1 Ionis Pharmaceuticals Company Details
        11.40.2 Ionis Pharmaceuticals Business Overview
        11.40.3 Ionis Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.40.4 Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021)
        11.40.5 Ionis Pharmaceuticals Recent Development
    11.41 Ixchel Pharma
    11.42 Khondrion
    11.43 Mimetogen Pharmaceuticals
    11.44 Mitotech
    11.45 M's Science
    11.46 Nanovector
    11.47 SanBio

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Ophthalmology Disorders Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Oral
    Table 3. Key Players of Injection
    Table 4. Key Players of External Use
    Table 5. Global Ophthalmology Disorders Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Ophthalmology Disorders Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Ophthalmology Disorders Drug Market Size by Regions (2016-2021) & (US$ Million)
    Table 8. Global Ophthalmology Disorders Drug Market Share by Regions (2016-2021)
    Table 9. Global Ophthalmology Disorders Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 10. Global Ophthalmology Disorders Drug Market Share by Regions (2022-2027)
    Table 11. Ophthalmology Disorders Drug Market Trends
    Table 12. Ophthalmology Disorders Drug Market Drivers
    Table 13. Ophthalmology Disorders Drug Market Challenges
    Table 14. Ophthalmology Disorders Drug Market Restraints
    Table 15. Global Ophthalmology Disorders Drug Revenue by Players (2016-2021) & (US$ Million)
    Table 16. Global Ophthalmology Disorders Drug Market Share by Players (2016-2021)
    Table 17. Global Top Ophthalmology Disorders Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ophthalmology Disorders Drug as of 2020)
    Table 18. Ranking of Global Top Ophthalmology Disorders Drug Companies by Revenue (US$ Million) in 2020
    Table 19. Global 5 Largest Players Market Share by Ophthalmology Disorders Drug Revenue (CR5 and HHI) & (2016-2021)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Ophthalmology Disorders Drug Product Solution and Service
    Table 22. Date of Enter into Ophthalmology Disorders Drug Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
    Table 25. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2016-2021)
    Table 26. Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 27. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 28. Global Ophthalmology Disorders Drug Market Size Share by Application (2016-2021) & (US$ Million)
    Table 29. Global Ophthalmology Disorders Drug Revenue Market Share by Application (2016-2021)
    Table 30. Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 31. Global Ophthalmology Disorders Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 32. North America Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
    Table 33. North America Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 34. North America Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
    Table 35. North America Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 36. North America Ophthalmology Disorders Drug Market Size by Country (2016-2021) & (US$ Million) 
    Table 37. North America Ophthalmology Disorders Drug Market Size by Country (2022-2027) & (US$ Million) 
    Table 38. Europe Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
    Table 39. Europe Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 40. Europe Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
    Table 41. Europe Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 42. Europe Ophthalmology Disorders Drug Market Size by Country (2016-2021) & (US$ Million) 
    Table 43. Europe Ophthalmology Disorders Drug Market Size by Country (2022-2027) & (US$ Million) 
    Table 44. Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
    Table 45. Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2016-2021) & (US$ Million) 
    Table 49. Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2022-2027) & (US$ Million) 
    Table 50. Latin America Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
    Table 51. Latin America Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Latin America Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
    Table 53. Latin America Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Latin America Ophthalmology Disorders Drug Market Size by Country (2016-2021) & (US$ Million) 
    Table 55. Latin America Ophthalmology Disorders Drug Market Size by Country (2022-2027) & (US$ Million) 
    Table 56. Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
    Table 57. Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2016-2021) & (US$ Million) 
    Table 61. Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2022-2027) & (US$ Million) 
    Table 62. Sanofi Company Details
    Table 63. Sanofi Business Overview
    Table 64. Sanofi Ophthalmology Disorders Drug Product
    Table 65. Sanofi Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 66. Sanofi Recent Development
    Table 67. Bayer Company Details
    Table 68. Bayer Business Overview
    Table 69. Bayer Ophthalmology Disorders Drug Product
    Table 70. Bayer Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 71. Bayer Recent Development
    Table 72. Bausch + Lomb Company Details
    Table 73. Bausch + Lomb Business Overview
    Table 74. Bausch + Lomb Ophthalmology Disorders Drug Product
    Table 75. Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 76. Bausch + Lomb Recent Development
    Table 77. Novartis Company Details
    Table 78. Novartis Business Overview
    Table 79. Novartis Ophthalmology Disorders Drug Product
    Table 80. Novartis Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 81. Novartis Recent Development
    Table 82. Usher Syndrome Company Details
    Table 83. Usher Syndrome Business Overview
    Table 84. Usher Syndrome Ophthalmology Disorders Drug Product
    Table 85. Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 86. Usher Syndrome Recent Development
    Table 87. Takeda Pharmaceutical Company Details
    Table 88. Takeda Pharmaceutical Business Overview
    Table 89. Takeda Pharmaceutical Ophthalmology Disorders Drug Product
    Table 90. Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 91. Takeda Pharmaceutical Recent Development
    Table 92. Roche Company Details
    Table 93. Roche Business Overview
    Table 94. Roche Ophthalmology Disorders Drug Product
    Table 95. Roche Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 96. Roche Recent Development
    Table 97. Pfizer Company Details
    Table 98. Pfizer Business Overview
    Table 99. Pfizer Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 100. Pfizer Recent Development
    Table 101. Allergan Company Details
    Table 102. Allergan Business Overview
    Table 103. Allergan Ophthalmology Disorders Drug Product
    Table 104. Allergan Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 105. Allergan Recent Development
    Table 106. Gilead Sciences Company Details
    Table 107. Gilead Sciences Business Overview
    Table 108. Gilead Sciences Ophthalmology Disorders Drug Product
    Table 109. Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 110. Gilead Sciences Recent Development
    Table 111. Kubota Pharmaceutical Company Details
    Table 112. Kubota Pharmaceutical Business Overview
    Table 113. Kubota Pharmaceutical Ophthalmology Disorders Drug Product
    Table 114. Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 115. Kubota Pharmaceutical Recent Development
    Table 116. Alkeus Pharmaceuticals Company Details
    Table 117. Alkeus Pharmaceuticals Business Overview
    Table 118. Alkeus Pharmaceuticals Ophthalmology Disorders Drug Product
    Table 119. Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 120. Alkeus Pharmaceuticals Recent Development
    Table 121. Astellas Pharma Company Details
    Table 122. Astellas Pharma Business Overview
    Table 123. Astellas Pharma Ophthalmology Disorders Drug Product
    Table 124. Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 125. Astellas Pharma Recent Development
    Table 126. Ferrer Corporate Company Details
    Table 127. Ferrer Corporate Business Overview
    Table 128. Ferrer Corporate Ophthalmology Disorders Drug Product
    Table 129. Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 130. Ferrer Corporate Recent Development
    Table 131. Amgen Inc Company Details
    Table 132. Amgen Inc Business Overview
    Table 133. Amgen Inc Ophthalmology Disorders Drug Product
    Table 134. Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 135. Amgen Inc Recent Development
    Table 136. Editas Medicine Inc Company Details
    Table 137. Editas Medicine Inc Business Overview
    Table 138. Editas Medicine Inc Ophthalmology Disorders Drug Product
    Table 139. Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 140. Editas Medicine Inc Recent Development
    Table 141. ProQR Therapeutics NV Company Details
    Table 142. ProQR Therapeutics NV Business Overview
    Table 143. ProQR Therapeutics NV Ophthalmology Disorders Drug Product
    Table 144. ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 145. ProQR Therapeutics NV Recent Development
    Table 146. ReNeuron Company Details
    Table 147. ReNeuron Business Overview
    Table 148. ReNeuron Ophthalmology Disorders Drug Product
    Table 149. ReNeuron Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 150. ReNeuron Recent Development
    Table 151. Amarantus BioScience Company Details
    Table 152. Amarantus BioScience Business Overview
    Table 153. Amarantus BioScience Ophthalmology Disorders Drug Product
    Table 154. Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 155. Amarantus BioScience Recent Development
    Table 156. Ocugen Company Details
    Table 157. Ocugen Business Overview
    Table 158. Ocugen Ophthalmology Disorders Drug Product
    Table 159. Ocugen Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 160. Ocugen Recent Development
    Table 161. ReGenX Biosciences Company Details
    Table 162. ReGenX Biosciences Business Overview
    Table 163. ReGenX Biosciences Ophthalmology Disorders Drug Product
    Table 164. ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 165. ReGenX Biosciences Recent Development
    Table 166. Sucampo Pharmaceuticals Company Details
    Table 167. Sucampo Pharmaceuticals Business Overview
    Table 168. Sucampo Pharmaceuticals Ophthalmology Disorders Drug Product
    Table 169. Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 170. Sucampo Pharmaceuticals Recent Development
    Table 171. Orphagen Pharmaceuticals Company Details
    Table 172. Orphagen Pharmaceuticals Business Overview
    Table 173. Orphagen Pharmaceuticals Ophthalmology Disorders Drug Product
    Table 174. Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 175. Orphagen Pharmaceuticals Recent Development
    Table 176. Okuvision Company Details
    Table 177. Okuvision Business Overview
    Table 178. Okuvision Ophthalmology Disorders DrugProduct
    Table 179. Okuvision Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 180. Okuvision Recent Development
    Table 181. Second Sight Medical Company Details
    Table 182. Second Sight Medical Business Overview
    Table 183. Second Sight Medical Ophthalmology Disorders Drug Product
    Table 184. Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 185. Second Sight Medical Recent Development
    Table 186. Acucela Company Details
    Table 187. Acucela Business Overview
    Table 188. Acucela Ophthalmology Disorders Drug Product
    Table 189. Acucela Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 190. Acucela Recent Development
    Table 191. Stealth BioTherapeutics Company Details
    Table 192. Stealth BioTherapeutics Business Overview
    Table 193. Stealth BioTherapeutics Ophthalmology Disorders Drug Product
    Table 194. Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 195. Stealth BioTherapeutics Recent Development
    Table 196. Sun Pharma Advanced Research Company Company Details
    Table 197. Sun Pharma Advanced Research Company Business Overview
    Table 198. Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Product
    Table 199. Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 200. Sun Pharma Advanced Research Company Recent Development
    Table 201. AmpliPhi Biosciences Company Details
    Table 202. AmpliPhi Biosciences Business Overview
    Table 203. AmpliPhi Biosciences Ophthalmology Disorders Drug Product
    Table 204. AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 205. AmpliPhi Biosciences Recent Development
    Table 206. Applied Genetic Technologies Company Details
    Table 207. Applied Genetic Technologies Business Overview
    Table 208. Applied Genetic Technologies Ophthalmology Disorders Drug Product
    Table 209. Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 210. Applied Genetic Technologies Recent Development
    Table 211. Asklepios BioPharmaceutical Company Details
    Table 212. Asklepios BioPharmaceutical Business Overview
    Table 213. Asklepios BioPharmaceutical Ophthalmology Disorders Drug Product
    Table 214. Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 215. Asklepios BioPharmaceutical Recent Development
    Table 216. Biovista Company Details
    Table 217. Biovista Business Overview
    Table 218. Biovista Ophthalmology Disorders Drug Product
    Table 219. Biovista Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 220. Biovista Recent Development
    Table 221. Spark Therapeutics Company Details
    Table 222. Spark Therapeutics Business Overview
    Table 223. Spark Therapeutics Ophthalmology Disorders Drug Product
    Table 224. Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 225. Spark Therapeutics Recent Development
    Table 226. Caladrius Biosciences Company Details
    Table 227. Caladrius Biosciences Business Overview
    Table 228. Caladrius Biosciences Ophthalmology Disorders Drug Product
    Table 229. Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 230. Caladrius Biosciences Recent Development
    Table 231. Dompe Farmaceutici Company Details
    Table 232. Dompe Farmaceutici Business Overview
    Table 233. Dompe Farmaceutici Ophthalmology Disorders Drug Product
    Table 234. Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 235. Dompe Farmaceutici Recent Development
    Table 236. Dormant Projects Company Details
    Table 237. Dormant Projects Business Overview
    Table 238. Dormant Projects Ophthalmology Disorders Drug Product
    Table 239. Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 240. Dormant Projects Recent Development
    Table 241. Grupo Ferrer Internacional Company Details
    Table 242. Grupo Ferrer Internacional Business Overview
    Table 243. Grupo Ferrer Internacional Ophthalmology Disorders Drug Product
    Table 244. Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 245. Grupo Ferrer Internacional Recent Development
    Table 246. ID Pharma Company Details
    Table 247. ID Pharma Business Overview
    Table 248. ID Pharma Ophthalmology Disorders Drug Product
    Table 249. ID Pharma Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 250. ID Pharma Recent Development
    Table 251. InFlectis BioScience Company Details
    Table 252. InFlectis BioScience Business Overview
    Table 253. InFlectis BioScience Ophthalmology Disorders Drug Product
    Table 254. InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 255. InFlectis BioScience Recent Development
    Table 256. Ionis Pharmaceuticals Company Details
    Table 257. Ionis Pharmaceuticals Business Overview
    Table 258. Ionis Pharmaceuticals Ophthalmology Disorders Drug Product
    Table 259. Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
    Table 260. Ionis Pharmaceuticals Recent Development
    Table 261. Ixchel Pharma Company Details
    Table 262. Khondrion Company Details
    Table 263. Mimetogen Pharmaceuticals Company Details
    Table 264. Mitotech Company Details
    Table 265. M's Science Company Details
    Table 266. Nanovector Company Details
    Table 267. SanBio Company Details
    Table 268. Research Programs/Design for This Report
    Table 269. Key Data Information from Secondary Sources
    Table 270. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Ophthalmology Disorders Drug Market Share by Type: 2020 VS 2027
    Figure 2. Oral Features
    Figure 3. Injection Features
    Figure 4. External Use Features
    Figure 5. Global Ophthalmology Disorders Drug Market Share by Application: 2020 VS 2027
    Figure 6. Juvenile Macular Degeneration (Stargardt Disease) Case Studies
    Figure 7. Leber Congenital Amaurosis (LCA) Case Studies
    Figure 8. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Case Studies
    Figure 9. Usher Syndrome Case Studies
    Figure 10. Retinitis Pigmentosa (Retinitis) Case Studies
    Figure 11. Ophthalmology Disorders Drug Report Years Considered
    Figure 12. Global Ophthalmology Disorders Drug Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 13. Global Ophthalmology Disorders Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 14. Global Ophthalmology Disorders Drug Market Share by Regions: 2020 VS 2027
    Figure 15. Global Ophthalmology Disorders Drug Market Share by Regions (2022-2027)
    Figure 16. Global Ophthalmology Disorders Drug Market Share by Players in 2020
    Figure 17. Global Top Ophthalmology Disorders Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ophthalmology Disorders Drug as of 2020
    Figure 18. The Top 10 and 5 Players Market Share by Ophthalmology Disorders Drug Revenue in 2020
    Figure 19. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2016-2021)
    Figure 20. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2022-2027)
    Figure 21. North America Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. North America Ophthalmology Disorders Drug Market Share by Type (2016-2027)
    Figure 23. North America Ophthalmology Disorders Drug Market Share by Application (2016-2027)
    Figure 24. North America Ophthalmology Disorders Drug Market Share by Country (2016-2027)
    Figure 25. United States Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Canada Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Ophthalmology Disorders Drug Market Share by Type (2016-2027)
    Figure 29. Europe Ophthalmology Disorders Drug Market Share by Application (2016-2027)
    Figure 30. Europe Ophthalmology Disorders Drug Market Share by Country (2016-2027)
    Figure 31. Germany Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. France Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. U.K. Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Italy Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Russia Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Nordic Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Ophthalmology Disorders Drug Market Share by Type (2016-2027)
    Figure 39. Asia-Pacific Ophthalmology Disorders Drug Market Share by Application (2016-2027)
    Figure 40. Asia-Pacific Ophthalmology Disorders Drug Market Share by Region (2016-2027)
    Figure 41. China Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Japan Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. South Korea Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Southeast Asia Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. India Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Australia Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Ophthalmology Disorders Drug Market Share by Type (2016-2027)
    Figure 49. Latin America Ophthalmology Disorders Drug Market Share by Application (2016-2027)
    Figure 50. Latin America Ophthalmology Disorders Drug Market Share by Country (2016-2027)
    Figure 51. Mexico Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Brazil Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Ophthalmology Disorders Drug Market Share by Type (2016-2027)
    Figure 55. Middle East & Africa Ophthalmology Disorders Drug Market Share by Application (2016-2027)
    Figure 56. Middle East & Africa Ophthalmology Disorders Drug Market Share by Country (2016-2027)
    Figure 57. Turkey Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Saudi Arabia Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. UAE Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Sanofi Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 61. Bayer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 62. Bausch + Lomb Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 63. Novartis Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 64. Usher Syndrome Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 65. Takeda Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 66. Roche Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 67. Pfizer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 68. Allergan Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 69. Gilead Sciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 70. Kubota Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 71. Alkeus Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 72. Astellas Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 73. Ferrer Corporate Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 74. Amgen Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 75. Editas Medicine Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 76. ProQR Therapeutics NV Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 77. ReNeuron Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 78. Amarantus BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 79. Ocugen Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 80. ReGenX Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 81. Sucampo Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 82. Orphagen Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 83. Okuvision Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 84. Second Sight Medical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 85. Acucela Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 86. Stealth BioTherapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 87. Sun Pharma Advanced Research Company Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 88. AmpliPhi Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 89. Applied Genetic Technologies Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 90. Asklepios BioPharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 91. Biovista Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 92. Spark Therapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 93. Caladrius Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 94. Dompe Farmaceutici Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 95. Dormant Projects Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 96. Grupo Ferrer Internacional Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 97. ID Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 98. InFlectis BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 99. Ionis Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
    Figure 100. Bottom-up and Top-down Approaches for This Report
    Figure 101. Data Triangulation
    Figure 102. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Sanofi
Bayer
Bausch + Lomb
Novartis
Usher Syndrome
Takeda Pharmaceutical
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma
Ferrer Corporate
Amgen Inc
Editas Medicine Inc
ProQR Therapeutics NV
ReNeuron
Amarantus BioScience
Ocugen
ReGenX Biosciences
Sucampo Pharmaceuticals
Orphagen Pharmaceuticals
Okuvision
Second Sight Medical
Acucela
Stealth BioTherapeutics
Sun Pharma Advanced Research Company
AmpliPhi Biosciences
Applied Genetic Technologies
Asklepios BioPharmaceutical
Biovista
Spark Therapeutics
Caladrius Biosciences
Dompe Farmaceutici
Dormant Projects
Grupo Ferrer Internacional
ID Pharma
InFlectis BioScience
Ionis Pharmaceuticals
Ixchel Pharma
Khondrion
Mimetogen Pharmaceuticals
Mitotech
M's Science
Nanovector
SanBio
Frequently Asked Questions
Ophthalmology Disorders Drug report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Ophthalmology Disorders Drug report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Ophthalmology Disorders Drug report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports